Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient

Congenital cytomegalovirus (CMV) infection occurs in approximately 1% of newborns and is the leading infectious cause of congenital birth defects. Female renal allograft recipients who develop CMV infection during pregnancy are at risk for both graft dysfunction and fetal morbidity. DNA-based analysis Of amniotic fluid (AF) from at-risk pregnancies has been suggested as an adjunct/ substitute for traditional culture We have shown that CMV-polymerase chain reaction of AF is a useful diagnostic test for congenital CMV infection. Using this test we diagnosed CMV infection in the fetus of a 30-year-old renal transplant recipient As termination was not an option for the family, the patient was extensively counseled and treated with oral ganciclovir. This resulted in clearance free of GMV of the virus from the AF and the delivery of a healthy newborn girl, This is the first reported case to our knowledge of successful use of disease. maternal ganciclovir to treat intrauterine CMV infection in a pregnant renal transplant recipient.